Simon R Lord

List of Publications by Year in descending order

26 papers	1,332 citations	759233 12 h-index	677142 22 g-index
26 all docs	26 docs citations	26 times ranked	2208 citing authors

#	Article	IF	Citations
1	Fatty Acid Uptake and Lipid Storage Induced by HIF-1Î± Contribute to Cell Growth and Survival after Hypoxia-Reoxygenation. Cell Reports, 2014, 9, 349-365.	6.4	498
2	Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. Lancet Oncology, The, 2019, 20, 1124-1135.	10.7	339
3	Integrated Pharmacodynamic Analysis Identifies Two Metabolic Adaption Pathways to Metformin in Breast Cancer. Cell Metabolism, 2018, 28, 679-688.e4.	16.2	92
4	Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 12452-12461.	7.1	86
5	BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC)â€"Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd).. Journal of Clinical Oncology, 2021, 39, 1023-1023.	1.6	49
6	The current status of risk-stratified breast screening. British Journal of Cancer, 2022, 126, 533-550.	6.4	47
7	Targeting OXPHOS and the electron transport chain in cancer; Molecular and therapeutic implications. Seminars in Cancer Biology, 2022, 86, 851-859.	9.6	39
8	Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours. British Journal of Cancer, 2021, 125, 520-527.	6.4	37
9	Transcriptomic analysis of human primary breast cancer identifies fatty acid oxidation as a target for metformin. British Journal of Cancer, 2020, 122, 258-265.	6.4	28
10	Radiogenomics Monitoring in Breast Cancer Identifies Metabolism and Immune Checkpoints as Early Actionable Mechanisms of Resistance to Anti-angiogenic Treatment. EBioMedicine, 2016, 10, 109-116.	6.1	27
11	Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer. Npj Breast Cancer, 2022, 8, 45.	5.2	16
12	Window of opportunity clinical trial designs to study cancer metabolism. British Journal of Cancer, 2020, 122, 45-51.	6.4	14
13	Angiogenesis - still a worthwhile target for breast cancer therapy?. Breast Cancer Research, 2010, 12, S19.	5.0	11
14	Heritable genetic variants in key cancer genes link cancer risk with anthropometric traits. Journal of Medical Genetics, 2021, 58, 392-399.	3.2	9
15	Neoadjuvant Window Studies of Metformin and Biomarker Development for Drugs Targeting Cancer Metabolism. Journal of the National Cancer Institute Monographs, 2015, 2015, 81-86.	2.1	8
16	VCAM-1â€"targeted MRI Improves Detection of the Tumor-brain Interface. Clinical Cancer Research, 2022, 28, 2385-2396.	7.0	7
17	Pharmacodynamic and Pharmacokinetic Markers For Anti-angiogenic Cancer Therapy: Implications for Dosing and Selection of Patients. European Journal of Drug Metabolism and Pharmacokinetics, 2018, 43, 137-153.	1.6	6
18	Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic. Exploration of Targeted Anti-tumor Therapy, 0, , 172-199.	0.8	6

#	ARTICLE	IF	CITATIONS
19	Characterising 18F-fluciclovine uptake in breast cancer through the use of dynamic PET/CT imaging. British Journal of Cancer, 2022, 126, 598-605.	6.4	4
20	Development and validation of clinical prediction models for breast cancer incidence and mortality: a protocol for a dual cohort study. BMJ Open, 2022, 12, e050828.	1.9	4
21	Early phase cancer clinical trials: design, ethics and future directions. British Journal of Hospital Medicine (London, England: 2005), 2015, 76, 409-413.	0.5	2
22	Abstract PD10-03: BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC): Results from Arm 1 D + paclitaxel (P), Arm 2 D+P + capivasertib (C), and Arm 5 D+P + oleclumab (O). Cancer Research, 2022, 82, PD10-03-PD10-03.	0.9	2
23	Can D-Dimer Measurement Reduce the Frequency of Radiological Assessment in Patients Receiving Palliative Imatinib for Gastrointestinal Stromal Tumor (GIST)?. Cancer Investigation, 2015, 33, 347-353.	1.3	1
24	Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer. The Cochrane Library, 2021, 2021, .	2.8	0
25	CGE22-097: Mapping the Mutational Landscape in Patients With Advanced Malignancies Enrolled to Early Phase Clinical Trials. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, CGE22-097.	4.9	0
26	Abstract 1247: Comprehensive molecular profiling to predict first-line immunochemotherapy outcomes in inoperable esophageal adenocarcinoma. Cancer Research, 2022, 82, 1247-1247.	0.9	0